Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs iShares 3 7 Year Treasury Bond ETF (IEI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs iShares 3 7 Year Treasury Bond ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $302.38 (market cap $39.89B), while iShares 3 7 Year Treasury Bond ETF trades at $116.77. Which is the better fit depends on your goals.
| ALNY | IEI | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Fixed Income |
52-Week High | $491.22 | $120.72 |
52-Week Low | $278.09 | $116.67 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
IEI (iShares 3-7 Year Treasury Bond ETF) trades at $116.77, down slightly by 0.06% amid broader market volatility. The technical picture remains bearish with moving averages signaling continued pressure, though oscillators show neutral momentum. Recent dividend payments of $0.36-$0.37 highlight the fund's income generation, while bond market uncertainty persists with mixed signals on Federal Reserve policy direction.
The outlook for IEI remains cautious as Treasury yields face upward pressure from inflation concerns and potential Fed rate hikes. While the ETF offers lower volatility than corporate bonds, competition from higher-yielding alternatives like Vanguard's bond ETFs presents headwinds. Key risks include interest rate sensitivity and shifting investor preferences toward higher-yield fixed income options.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →
